Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck

Nadeem Riaz, Eric Sherman, Lawrence Koutcher, Lauren Shapiro, Nora Katabi, Zhigang Zhang, Weiji Shi, Mathew Fury, Richard Wong, Suzanne Wolden, Shyam Rao, Nancy Lee

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objectives: We previously reported inferior outcomes for locally advanced head and neck cancer treated with cetuximab (C225) versus cisplatin (CDDP). We now examine if this difference persists when accounting for HPV status and update outcomes on the entire cohort. Materials and Methods: From 3/106 to 4/1/08, 174 locally advanced head and neck cancer patients received definitive treatment with RT and CDDP (n = 125) or RT and C225 (n = 49). Of these, 62 patients had tissue available for HPV analysis. Results: The median follow-up was 47 months. The 3-year locoregional failure, disease-free survival, and overall survival for CDDP versus C225 were 5.7% versus 40.2% (P < 0.0001), 85.1% versus 35.4% (P < 0.0001), and 90.0% versus 56.6% (P < 0.0001), respectively. In the subset with tissue, there was no difference in rates of HPV or p16 positivity between the 2 groups. In this subset, the 3-year loco-regional failure, disease-free survival, and overall survival for CDDP versus C225 were 5.3% versus 32.0% (P = 0.01), 86.8% versus 43.2% (P = 0.002), and 86.7% versus 76.9% (P = 0.09), respectively. Multivariate analysis continued to show a benefit for CDDP. Conclusions: With longer follow-up and the inclusion of HPV and p16 status for about one third of patients where tissue was available, we continued to find superior outcomes with concurrent CDDP versus C225.

Original languageEnglish (US)
Pages (from-to)27-31
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume39
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Chemoradiotherapy
Cisplatin
Head and Neck Neoplasms
Disease-Free Survival
Survival
Cetuximab
Carcinoma, squamous cell of head and neck
Multivariate Analysis

Keywords

  • Cetuximab
  • Cisplatin
  • Head and neck cancer
  • HPV
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. / Riaz, Nadeem; Sherman, Eric; Koutcher, Lawrence; Shapiro, Lauren; Katabi, Nora; Zhang, Zhigang; Shi, Weiji; Fury, Mathew; Wong, Richard; Wolden, Suzanne; Rao, Shyam; Lee, Nancy.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 39, No. 1, 01.01.2016, p. 27-31.

Research output: Contribution to journalArticle

Riaz, N, Sherman, E, Koutcher, L, Shapiro, L, Katabi, N, Zhang, Z, Shi, W, Fury, M, Wong, R, Wolden, S, Rao, S & Lee, N 2016, 'Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 39, no. 1, pp. 27-31. https://doi.org/10.1097/COC.0000000000000006
Riaz, Nadeem ; Sherman, Eric ; Koutcher, Lawrence ; Shapiro, Lauren ; Katabi, Nora ; Zhang, Zhigang ; Shi, Weiji ; Fury, Mathew ; Wong, Richard ; Wolden, Suzanne ; Rao, Shyam ; Lee, Nancy. / Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2016 ; Vol. 39, No. 1. pp. 27-31.
@article{f967a644554c4038becd098c147a1a0e,
title = "Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck",
abstract = "Objectives: We previously reported inferior outcomes for locally advanced head and neck cancer treated with cetuximab (C225) versus cisplatin (CDDP). We now examine if this difference persists when accounting for HPV status and update outcomes on the entire cohort. Materials and Methods: From 3/106 to 4/1/08, 174 locally advanced head and neck cancer patients received definitive treatment with RT and CDDP (n = 125) or RT and C225 (n = 49). Of these, 62 patients had tissue available for HPV analysis. Results: The median follow-up was 47 months. The 3-year locoregional failure, disease-free survival, and overall survival for CDDP versus C225 were 5.7{\%} versus 40.2{\%} (P < 0.0001), 85.1{\%} versus 35.4{\%} (P < 0.0001), and 90.0{\%} versus 56.6{\%} (P < 0.0001), respectively. In the subset with tissue, there was no difference in rates of HPV or p16 positivity between the 2 groups. In this subset, the 3-year loco-regional failure, disease-free survival, and overall survival for CDDP versus C225 were 5.3{\%} versus 32.0{\%} (P = 0.01), 86.8{\%} versus 43.2{\%} (P = 0.002), and 86.7{\%} versus 76.9{\%} (P = 0.09), respectively. Multivariate analysis continued to show a benefit for CDDP. Conclusions: With longer follow-up and the inclusion of HPV and p16 status for about one third of patients where tissue was available, we continued to find superior outcomes with concurrent CDDP versus C225.",
keywords = "Cetuximab, Cisplatin, Head and neck cancer, HPV, Radiation",
author = "Nadeem Riaz and Eric Sherman and Lawrence Koutcher and Lauren Shapiro and Nora Katabi and Zhigang Zhang and Weiji Shi and Mathew Fury and Richard Wong and Suzanne Wolden and Shyam Rao and Nancy Lee",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/COC.0000000000000006",
language = "English (US)",
volume = "39",
pages = "27--31",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck

AU - Riaz, Nadeem

AU - Sherman, Eric

AU - Koutcher, Lawrence

AU - Shapiro, Lauren

AU - Katabi, Nora

AU - Zhang, Zhigang

AU - Shi, Weiji

AU - Fury, Mathew

AU - Wong, Richard

AU - Wolden, Suzanne

AU - Rao, Shyam

AU - Lee, Nancy

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objectives: We previously reported inferior outcomes for locally advanced head and neck cancer treated with cetuximab (C225) versus cisplatin (CDDP). We now examine if this difference persists when accounting for HPV status and update outcomes on the entire cohort. Materials and Methods: From 3/106 to 4/1/08, 174 locally advanced head and neck cancer patients received definitive treatment with RT and CDDP (n = 125) or RT and C225 (n = 49). Of these, 62 patients had tissue available for HPV analysis. Results: The median follow-up was 47 months. The 3-year locoregional failure, disease-free survival, and overall survival for CDDP versus C225 were 5.7% versus 40.2% (P < 0.0001), 85.1% versus 35.4% (P < 0.0001), and 90.0% versus 56.6% (P < 0.0001), respectively. In the subset with tissue, there was no difference in rates of HPV or p16 positivity between the 2 groups. In this subset, the 3-year loco-regional failure, disease-free survival, and overall survival for CDDP versus C225 were 5.3% versus 32.0% (P = 0.01), 86.8% versus 43.2% (P = 0.002), and 86.7% versus 76.9% (P = 0.09), respectively. Multivariate analysis continued to show a benefit for CDDP. Conclusions: With longer follow-up and the inclusion of HPV and p16 status for about one third of patients where tissue was available, we continued to find superior outcomes with concurrent CDDP versus C225.

AB - Objectives: We previously reported inferior outcomes for locally advanced head and neck cancer treated with cetuximab (C225) versus cisplatin (CDDP). We now examine if this difference persists when accounting for HPV status and update outcomes on the entire cohort. Materials and Methods: From 3/106 to 4/1/08, 174 locally advanced head and neck cancer patients received definitive treatment with RT and CDDP (n = 125) or RT and C225 (n = 49). Of these, 62 patients had tissue available for HPV analysis. Results: The median follow-up was 47 months. The 3-year locoregional failure, disease-free survival, and overall survival for CDDP versus C225 were 5.7% versus 40.2% (P < 0.0001), 85.1% versus 35.4% (P < 0.0001), and 90.0% versus 56.6% (P < 0.0001), respectively. In the subset with tissue, there was no difference in rates of HPV or p16 positivity between the 2 groups. In this subset, the 3-year loco-regional failure, disease-free survival, and overall survival for CDDP versus C225 were 5.3% versus 32.0% (P = 0.01), 86.8% versus 43.2% (P = 0.002), and 86.7% versus 76.9% (P = 0.09), respectively. Multivariate analysis continued to show a benefit for CDDP. Conclusions: With longer follow-up and the inclusion of HPV and p16 status for about one third of patients where tissue was available, we continued to find superior outcomes with concurrent CDDP versus C225.

KW - Cetuximab

KW - Cisplatin

KW - Head and neck cancer

KW - HPV

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=84957844436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957844436&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000006

DO - 10.1097/COC.0000000000000006

M3 - Article

C2 - 24401670

AN - SCOPUS:84957844436

VL - 39

SP - 27

EP - 31

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -